ATM-dependent DNA damage-response pathway as a determinant in chronic myelogenous leukemia

DNA Repair

Volumn 12, Issue 7, 2013, Pages 500-507

  Takagi, Masatoshi ^a   Sato, Masaki ^a   Piao, Jinhua ^a   Miyamoto, Satoshi ^a   Isoda, Takeshi ^a   Kitagawa, Masanobu ^a   Honda, Hiroaki ^b   Mizutani, Shuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

ATM; BCR ABL; Chronic myelogenous leukemia; DNA damage response

Indexed keywords

BCR ABL PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ARTICLE; ATAXIA TELANGIECTASIA MUTATED GENE; BLAST CELL CRISIS; BONE MARROW; CANCER GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DISEASE PREDISPOSITION; DNA DAMAGE; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; GENE EXPRESSION; GENOMIC INSTABILITY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BLAST CRISIS; BONE MARROW; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; DNA-BINDING PROTEINS; FUSION PROTEINS, BCR-ABL; MICE; MICE, KNOCKOUT; MUTATION; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA; MUS; MUS MUSCULUS;

EID: 84878647132     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2013.04.022     Document Type: Article

References (40)

1. Jabbour E., Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am. J. Hematol. 2012, 87:1037-1045.
2. Khorashad J.S., Kelley T.W., Szankasi P., Mason C.C., Soverini S., Adrian L.T., Eide C.A., Zabriskie M.S., Lange T., Estrada J.C., Pomicter A.D., Eiring A.M., Kraft I.L., Anderson D.J., Gu Z., Alikian M., Reid A.G., Foroni L., Marin D., Druker B.J., O'Hare T., Deininger M.W. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013, 121:489-498.
3. Rink L., Slupianek A., Stoklosa T., Nieborowska-Skorska M., Urbanska K., Seferynska I., Reiss K., Skorski T. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells. Blood 2007, 110:651-660.
4. Stoklosa T., Slupianek A., Datta M., Nieborowska-Skorska M., Nowicki M.O., Koptyra M., Skorski T. BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance. Cell Cycle 2004, 3:1463-1472.
5. Calabretta B., Perrotti D. The biology of CML blast crisis. Blood 2004, 103:4010-4022.
6. Vorechovsky I., Luo L., Dyer M.J., Catovsky D., Amlot P.L., Yaxley J.C., Foroni L., Hammarstrom L., Webster A.D., Yuille M.A. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat. Genet. 1997, 17:96-99.
7. Stilgenbauer S., Schaffner C., Winkler D., Ott G., Leupolt E., Bentz M., Moller P., Muller-Hermelink H.K., James M.R., Lichter P., Dohner H. The ATM gene in the pathogenesis of mantle-cell lymphoma. Ann. Oncol. 2000, 11(Suppl. 1):127-130.
8. Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P.J., Moss P.A., Taylor A.M. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999, 353:26-29.
9. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Orntoft T., Lukas J., Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
10. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., Takaoka M., Nakagawa H., Tort F., Fugger K., Johansson F., Sehested M., Andersen C.L., Dyrskjot L., Orntoft T., Lukas J., Kittas C., Helleday T., Halazonetis T.D., Bartek J., Gorgoulis V.G. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
11. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
12. Horibe S., Takagi M., Unno J., Nagasawa M., Morio T., Arai A., Miura O., Ohta M., Kitagawa M., Mizutani S. DNA damage check points prevent leukemic transformation in myelodysplastic syndrome. Leukemia 2007, 21:2195-2198.
13. Boehrer S., Ades L., Tajeddine N., Hofmann W.K., Kriener S., Bug G., Ottmann O.G., Ruthardt M., Galluzzi L., Fouassier C., Tailler M., Olaussen K.A., Gardin C., Eclache V., de Botton S., Thepot S., Fenaux P., Kroemer G. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene 2009, 28:2205-2218.
14. Daley G.Q., Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:9312-9316.
15. Honda H., Oda H., Suzuki T., Takahashi T., Witte O.N., Ozawa K., Ishikawa T., Yazaki Y., Hirai H. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. Blood 1998, 91:2067-2075.
16. Herzog K.H., Chong M.J., Kapsetaki M., Morgan J.I., McKinnon P.J. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 1998, 280:1089-1091.
17. Chakraborty S., Stark J.M., Sun C.L., Modi H., Chen W., O'Connor T.R., Forman S.J., Bhatia S., Bhatia R. Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining. Blood 2012, 119:6187-6197.
18. Honda H., Hirai H. Model mice for BCR/ABL-positive leukemias. Blood Cells Mol. Dis. 2001, 27:265-278.
19. Nagamachi A., Yamasaki N., Miyazaki K., Oda H., Miyazaki M., Honda Z., Kominami R., Inaba T., Honda H. Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model. Cancer Sci. 2009, 100:1219-1226.
20. Honda H., Ushijima T., Wakazono K., Oda H., Tanaka Y., Aizawa S., Ishikawa T., Yazaki Y., Hirai H. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood 2000, 95:1144-1150.
21. Isoda T., Takagi M., Piao J., Nakagama S., Sato M., Masuda K., Ikawa T., Azuma M., Morio T., Kawamoto H., Mizutani S. Process for immune defect and chromosomal translocation during early thymocyte development lacking ATM. Blood 2012, 120:789-799.
22. Radich J.P. The Biology of CML blast crisis. Hematology 2007, 384-391.
23. Ahuja H., Bar-Eli M., Advani S.H., Benchimol S., Cline M.J. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:6783-6787.
24. Mullighan C.G., Miller C.B., Radtke I., Phillips L.A., Dalton J., Ma J., White D., Hughes T.P., Le Beau M.M., Pui C.H., Relling M.V., Shurtleff S.A., Downing J.R. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453:110-114.
25. Skorski T. Genomic instability: the cause and effect of BCR/ABL tyrosine kinase. Curr. Hematol. Malig. Rep. 2007, 2:69-74.
26. Poplawski T., Blasiak J. BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells. Mol. Biol. Rep. 2010, 37:2309-2315.
27. Valeri A., Alonso-Ferrero M.E., Rio P., Pujol M.R., Casado J.A., Perez L., Jacome A., Agirre X., Calasanz M.J., Hanenberg H., Surralles J., Prosper F., Albella B., Bueren J.A. Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells. PLoS ONE 2010, 5:e15525.
28. Deutsch E., Jarrousse S., Buet D., Dugray A., Bonnet M.L., Vozenin-Brotons M.C., Guilhot F., Turhan A.G., Feunteun J., Bourhis J. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 2003, 101:4583-4588.
29. Slupianek A., Jozwiakowski S.K., Gurdek E., Skorski T. BCR/ABL kinase interacts with and phosphorylates the RAD51 paralog, RAD51B. Leukemia 2009, 23:2308-2310.
30. Slupianek A., Schmutte C., Tombline G., Nieborowska-Skorska M., Hoser G., Nowicki M.O., Pierce A.J., Fishel R., Skorski T. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol. Cell 2001, 8:795-806.
31. Yasuda T., Shirakata M., Iwama A., Ishii A., Ebihara Y., Osawa M., Honda K., Shinohara H., Sudo K., Tsuji K., Nakauchi H., Iwakura Y., Hirai H., Oda H., Yamamoto T., Yamanashi Y. Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia. J. Exp. Med. 2004, 200:1681-1687.
32. Melo J.V., Kumberova A., van Dijk A.G., Goldman J.M., Yuille M.R. Investigation on the role of the ATM gene in chronic myeloid leukaemia. Leukemia 2001, 15:1448-1450.
33. Swift M., Morrell D., Cromartie E., Chamberlin A.R., Skolnick M.H., Bishop D.T. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am. J. Hum. Genet. 1986, 39:573-583.
34. Thompson D., Duedal S., Kirner J., McGuffog L., Last J., Reiman A., Byrd P., Taylor M., Easton D.F. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl. Cancer Inst. 2005, 97:813-822.
35. Renwick A., Thompson D., Seal S., Kelly P., Chagtai T., Ahmed M., North B., Jayatilake H., Barfoot R., Spanova K., McGuffog L., Evans D.G., Eccles D., Easton D.F., Stratton M.R., Rahman N. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 2006, 38:873-875.
36. Liberzon E., Avigad S., Stark B., Zilberstein J., Freedman L., Gorfine M., Gavriel H., Cohen I.J., Goshen Y., Yaniv I., Zaizov R. Germ-line ATM gene alterations are associated with susceptibility to sporadic T-cell acute lymphoblastic leukemia in children. Genes Chromosomes Cancer 2004, 39:161-166.
37. Lu S., Shen K., Wang Y., Santner S.J., Chen J., Brooks S.C., Wang Y.A. Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors. Carcinogenesis 2006, 27:848-855.
38. Mao J.H., Wu D., DelRosario R., Castellanos A., Balmain A., Perez-Losada J. Atm heterozygosity does not increase tumor susceptibility to ionizing radiation alone or in a p53 heterozygous background. Oncogene 2008, 27:6596-6600.
39. Barlow C., Eckhaus M.A., Schaffer A.A., Wynshaw-Boris A. Atm haploinsufficiency results in increased sensitivity to sublethal doses of ionizing radiation in mice. Nat. Genet. 1999, 21:359-360.
40. Shigeta T., Takagi M., Delia D., Chessa L., Iwata S., Kanke Y., Asada M., Eguchi M., Mizutani S. Defective control of apoptosis and mitotic spindle checkpoint in heterozygous carriers of ATM mutations. Cancer Res. 1999, 59:2602-2607.